Literature DB >> 17873895

Wnt signaling pathway analysis in renal cell carcinoma in young patients.

Elisabeth Bruder1, Holger Moch, David Ehrlich, Ivo Leuschner, Dieter Harms, Pedram Argani, Jakob Briner, Norbert Graf, Barbara Selle, Alex Rufle, Michael Paulussen, Robert Koesters.   

Abstract

Renal cell carcinomas in young patients constitute a morphologically and genetically heterogeneous group. Twenty percent belong to the newly recognized Xp11.2 translocation-associated family and rare tumors arise from nephroblastoma. Aberrant Wnt signaling through beta-catenin mutation has been implicated in nephroblastoma pathogenesis and has been found to synergize with WT1 mutations. To characterize Wnt signaling activity in renal cell carcinomas in young patients, we gathered 34 tumors (three clear cell, ten Xp11.2 translocation associated, five papillary, two chromophobe, two collecting duct, one neuroblastoma associated, eight unclassified renal cell carcinomas, and three carcinomas combined with nephroblastoma) from patients less than 22 years. Expression of beta-catenin, its homologue gamma-catenin, and of WT1 was assessed by immunohistochemistry in 30 tumors, and sequence analysis of CTNNB1, CTNNG1, and WT1 genes was performed in 25 tumors. Cytoplasmic beta-catenin accumulation was demonstrated in two papillary carcinomas, one neuroblastoma-associated carcinoma, and two carcinomas arising from nephroblastoma. The pattern of gamma-catenin expression paralleled that of beta-catenin but its signal intensity was lower in 22, equal in 7, and stronger only in 1 tumor, respectively. Four tumors showed nuclear WT1 expression. One Xp11.2 translocation-associated carcinoma presented a rare intronic CTNNB1 single nucleotide polymorphism and cytoplasmic beta-catenin accumulation. There were no further CTNNB1 or CTNNG1 sequence alterations. A WT1 mutation was found in the nephroblastoma component of a carcinoma arising from nephroblastoma. These findings suggest Wnt signaling pathway activation only in a minority of renal cell carcinomas in young patients. CTNNB1 mutations are rare events. Cytoplasmic beta-catenin accumulation in an Xp11.2-associated carcinoma suggests potential interaction of Wnt signaling components with microphthalmia transcription factor family also in Xp11.2 translocation carcinomas. WT1 mutation in the nephroblastoma component of a mixed-type renal cell carcinoma provides direct evidence for clonal independence of nephroblastoma and carcinoma components in this exceptional tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873895     DOI: 10.1038/modpathol.3800957

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Disruption of N-linked glycosylation promotes proteasomal degradation of the human ATP-binding cassette transporter ABCA3.

Authors:  Michael F Beers; Ming Zhao; Yaniv Tomer; Scott J Russo; Peggy Zhang; Linda W Gonzales; Susan H Guttentag; Surafel Mulugeta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-18       Impact factor: 5.464

2.  Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.

Authors:  Dorothee Pflueger; Andrea Sboner; Martina Storz; Jasmine Roth; Eva Compérat; Elisabeth Bruder; Mark A Rubin; Peter Schraml; Holger Moch
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

3.  UBE3C promotes growth and metastasis of renal cell carcinoma via activating Wnt/β-catenin pathway.

Authors:  Ji Ling Wen; Xiao Fei Wen; Rong Bing Li; Yong Chao Jin; Xue Lei Wang; Lan Zhou; Hui Xing Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

4.  Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.

Authors:  Yicheng Chen; Qiaoli Huang; Hua Zhou; Yueping Wang; Xian Hu; Tao Li
Journal:  Oncotarget       Date:  2016-08-02

5.  Oxymatrine Inhibits Renal Cell Carcinoma Progression by Suppressing β-Catenin Expression.

Authors:  Yinshan Jin; Jiannan Liu; Yadong Liu; Yang Liu; Guiying Guo; Shiliang Yu; Ruihua An
Journal:  Front Pharmacol       Date:  2020-06-05       Impact factor: 5.810

6.  NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway.

Authors:  Jiancheng Zhou; Jiawei Lai; Yongyi Cheng; Weixing Qu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-29       Impact factor: 2.650

7.  WNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/β-catenin pathway.

Authors:  Ren-Jun Hsu; Jar-Yi Ho; Tai-Lung Cha; Dah-Shyong Yu; Chieh-Lin Wu; Wei-Ping Huang; Pauling Chu; Ying-Hsin Chen; Jiann-Torng Chen; Cheng-Ping Yu
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

8.  Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma.

Authors:  Jar-Yi Ho; Ren-Jun Hsu; Chieh-Lin Wu; Wen-Liang Chang; Tai-Lung Cha; Dah-Shyong Yu; Cheng-Ping Yu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-26       Impact factor: 2.629

9.  Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma.

Authors:  Stephan Kruck; Christian Eyrich; Marcus Scharpf; Karl-Dietrich Sievert; Falco Fend; Arnulf Stenzl; Jens Bedke
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

10.  Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling.

Authors:  Alessia Calcagnì; Lotte Kors; Eric Verschuren; Rossella De Cegli; Nicolina Zampelli; Edoardo Nusco; Stefano Confalonieri; Giovanni Bertalot; Salvatore Pece; Carmine Settembre; Gabriel G Malouf; Jaklien C Leemans; Emile de Heer; Marco Salvatore; Dorien Jm Peters; Pier Paolo Di Fiore; Andrea Ballabio
Journal:  Elife       Date:  2016-09-26       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.